Failures of precision therapies should be not underestimated, e.g., quinidine (and its derivatives) in KCNT1-activating mutations or phenytoin in patients with GoF SCN8A mutations and encephalopathy. The gene discussed is SCN8A; the disease is Encephalopathy.